In Myasthenia Gravis, Antibodies Pass Open-Label Tests In Myasthenia Gravis, Antibodies Pass Open-Label Tests

Researchers presented data from an open-label extension study following the phase 3 MycarinG trial of rozanolixizumab and the ADAPT-SC+ study of efgartigimod.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news